Pang Yuhui, Qi Xiaoyu, Qin Jiayue, Zhai Xiaoran, Wang Rongxiao, Cao Jianzhu, Zhang Na, Liu Jinxia, Li Jianying, Wu Weihai, Wei Shanshan, Zhang Jingjing, Zhang Shaofei, Zhang Yaochen, Yue Yan
Department of Hematology, Shijiazhuang Pingan Hospital, Shijiazhuang, China.
Department of Medical Affairs, Acornmed Biotechnology Co., Ltd., Beijing, China.
Front Immunol. 2024 Nov 20;15:1493398. doi: 10.3389/fimmu.2024.1493398. eCollection 2024.
Pyruvate kinase deficiency (PKD) is an autosomal recessive genetic disease caused by mutations in the gene. To date, the clinical manifestations of PKD are heterogeneous, ranging from fetal anemia, neonatal jaundice, and severe chronic hemolytic anemia to fully compensated hemolytic anemia. Successful cases of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for PKD have been reported, however, the number of cases is very small, and experiences are very limited. Here, we report two successful cases involving our modified conditioning regimen. This approach is suitable for patients with severe transfusion dependence. In conclusion, for PKD patients with severe transfusion dependence, allo-HSCT is an option and is currently a safe and effective way to completely eliminate the need for transfusions of drugs, such as Mitapivat, or genetic therapies and allow the patient to return to normal life.
丙酮酸激酶缺乏症(PKD)是一种由该基因中的突变引起的常染色体隐性遗传病。迄今为止,PKD的临床表现具有异质性,从胎儿贫血、新生儿黄疸、严重慢性溶血性贫血到完全代偿性溶血性贫血不等。已有关于PKD异基因造血干细胞移植(allo-HSCT)成功案例的报道,然而,案例数量非常少,经验也非常有限。在此,我们报告两例采用我们改良预处理方案的成功案例。这种方法适用于严重依赖输血的患者。总之,对于严重依赖输血的PKD患者,allo-HSCT是一种选择,目前是完全消除对米他匹韦等药物输血需求或基因治疗需求并使患者恢复正常生活的安全有效方法。